Neurocrine Biosciences News (NASDAQ:NBIX)

DateTimeSource
Headline
10/23/20174:57PMPRNUSNeurocrine Granted FDA Orphan Drug Designation for Valbenazine for the Treatment of Pediatric Patients With Tourette Syndrome
Neurocrine Granted FDA Orphan Drug Designation for Valbenazine for the Treatment of Pediatric Patients With Tourette Syndrome PR Newswire SAN DIEGO, Oct. 23, 2017 SAN DIEGO, Oct. 23, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that valbenazine, a novel selective vesicular monoamine... More...>>
10/05/20177:00AMPRNUSNeurocrine Announces FDA Approval of 80 mg INGREZZA® (valbenazine) Capsules for the Treatment of Adults with Tardive Dyskine...
Neurocrine Announces FDA Approval of 80 mg INGREZZA® (valbenazine) Capsules for the Treatment of Adults with Tardive Dyskinesia (TD) First and only TD therapy taken as one capsule, once per day; new 80 mg capsule expected to be available for patients within two weeks INBRACE™ program offers patients access to treatment... More...>>
09/15/20179:25AMPRNUSNeurocrine Announces Data on the Real-World Patient Impact of TD from the RE-KINECT Study to be Presented at the 2017 Annual ...
Neurocrine Announces Data on the Real-World Patient Impact of TD from the RE-KINECT Study to be Presented at the 2017 Annual Psych Congress PR Newswire SAN DIEGO, Sept. 15, 2017 SAN DIEGO, Sept. 15, 2017 /PRNewswire/ -- Neurocrine Biosciences Inc. (NASDAQ: NBIX) announced today upcoming poster presentations at the 2017... More...>>
09/06/20172:00PMPRNUSNeurocrine Biosciences to Present at the Morgan Stanley 15th Annual Global Healthcare Conference
Neurocrine Biosciences to Present at the Morgan Stanley 15th Annual Global Healthcare Conference Live Audio Webcast Will be on September 11, 2017 PR Newswire SAN DIEGO, Sept. 6, 2017 SAN DIEGO, Sept. 6, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, CEO of Neurocrine... More...>>
09/06/20178:01AMPRNUSAbbVie Submits New Drug Application to U.S. FDA for Investigational Oral Treatment Elagolix for the Management of Endometrios...
AbbVie Submits New Drug Application to U.S. FDA for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain - In clinical studies, elagolix demonstrated superiority compared to placebo in reducing three types of endometriosis-associated pain - daily menstrual pelvic pain, non-menstrual... More...>>
08/30/20171:00PMPRNUSNeurocrine Biosciences to Present at the Baird 2017 Global Healthcare Conference
Neurocrine Biosciences to Present at the Baird 2017 Global Healthcare Conference Live Audio Webcast Will be on September 6, 2017 PR Newswire SAN DIEGO, Aug. 30, 2017 SAN DIEGO, Aug. 30, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, CEO of Neurocrine Biosciences, will... More...>>
08/03/20174:01PMPRNUSNeurocrine Biosciences Reports Second Quarter 2017 Results
Neurocrine Biosciences Reports Second Quarter 2017 Results - INGREZZA® Net Product Sales of $6.3 Million in Initial Two Months of Commercialization as the First and Only U.S. Food and Drug Administration Approved Product for the Treatment of Tardive Dyskinesia - Partner AbbVie Expected to Submit Elagolix NDA for Endometriosis... More...>>
07/28/20171:00PMPRNUSNeurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2017 Results
Neurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2017 Results Conference Call and Webcast Scheduled for August 3, 2017 PR Newswire SAN DIEGO, July 28, 2017 SAN DIEGO, July 28, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report... More...>>
07/21/20179:28AMPRNUSNeurocrine Biosciences Announces the Appointment of Julie Cooke as Chief People Officer
Neurocrine Biosciences Announces the Appointment of Julie Cooke as Chief People Officer PR Newswire SAN DIEGO, July 21, 2017 SAN DIEGO, July 21, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused on neurological and endocrine related disorders, announced that Julie Cooke is... More...>>
06/09/20171:00PMPRNUSNeurocrine Biosciences to Present at the Goldman Sachs 38th Annual Global Healthcare Conference
Neurocrine Biosciences to Present at the Goldman Sachs 38th Annual Global Healthcare Conference Live Audio Webcast Will be on June 15, 2017 PR Newswire SAN DIEGO, June 9, 2017 SAN DIEGO, June 9, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, CEO of Neurocrine Biosciences... More...>>
06/02/20179:25AMPRNUSNeurocrine Announces Presentations Related to INGREZZA® (valbenazine) Capsules at the 21st International Congress of Parkins...
Neurocrine Announces Presentations Related to INGREZZA® (valbenazine) Capsules at the 21st International Congress of Parkinson's Disease and Movement Disorders PR Newswire SAN DIEGO, June 2, 2017 SAN DIEGO, June 2, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today the upcoming presentation... More...>>
06/01/20174:18PMPRNUSNeurocrine Biosciences to Present at the Jefferies 2017 Global Healthcare Conference
Neurocrine Biosciences to Present at the Jefferies 2017 Global Healthcare Conference Live Audio Webcast Will be on June 8, 2017 PR Newswire SAN DIEGO, June 1, 2017 SAN DIEGO, June 1, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, CEO of Neurocrine Biosciences, will... More...>>
05/23/20174:01PMPRNUSNeurocrine Announces Phase II Results of VMAT2 Inhibitor INGREZZA® For Treatment of Tourette Syndrome
Neurocrine Announces Phase II Results of VMAT2 Inhibitor INGREZZA® For Treatment of Tourette Syndrome Study Provides Clear Path Forward for Future Pivotal Studies Company to Host Conference Call and Webcast Tuesday, May 23rd at 5:00 P.M. ET / 2:00 P.M. PT PR Newswire SAN DIEGO, May 23, 2017 SAN DIEGO, May 23, 2017 /PRNewswire/... More...>>
05/18/20174:05PMPRNUSNeurocrine Announces INGREZZA® (valbenazine) Capsules Pharmacokinetic Profile and Long-Term Data to be Presented at the 2017...
Neurocrine Announces INGREZZA® (valbenazine) Capsules Pharmacokinetic Profile and Long-Term Data to be Presented at the 2017 American Psychiatric Association Annual Meeting PR Newswire SAN DIEGO, May 18, 2017 SAN DIEGO, May 18, 2017 /PRNewswire/ -- Neurocrine Biosciences Inc. (NASDAQ: NBIX) announced today the upcoming... More...>>
05/17/201712:00PMPRNUSAbbVie Presents Pivotal Phase 3 Data on Investigational Treatment Elagolix at the World Congress on Endometriosis
AbbVie Presents Pivotal Phase 3 Data on Investigational Treatment Elagolix at the World Congress on Endometriosis - Primary and secondary efficacy and safety data to be presented from two pivotal Phase 3 studies evaluating the use of elagolix in endometriosis-associated pain - New hormone and ovulation data will also be... More...>>
05/11/20173:00PMPRNUSNeurocrine Biosciences to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference
Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference Live Audio Webcast Will be on May 17, 2017 PR Newswire SAN DIEGO, May 11, 2017 SAN DIEGO, May 11, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, CEO of Neurocrine Biosciences... More...>>
05/09/20174:01PMPRNUSNeurocrine Biosciences Reports First Quarter 2017 Results
Neurocrine Biosciences Reports First Quarter 2017 Results - Launched INGREZZA® Commercially after Approval by the U.S. Food and Drug Administration for the Treatment of Tardive Dyskinesia - Phase II Study Results of INGREZZA in Pediatric Tourette Syndrome Expected in May 2017 - Acquired U.S. and Canadian Rights to Opicapone... More...>>
05/03/20171:00PMPRNUSNeurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2017 Results
Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2017 Results Conference Call and Webcast Scheduled for Tuesday, May 9, 2017 PR Newswire SAN DIEGO, May 3, 2017 SAN DIEGO, May 3, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report... More...>>
05/02/20175:04PMPRNUSNeurocrine Biosciences, Inc. Announces Closing of Offering of $517.5 Million of Convertible Senior Notes
Neurocrine Biosciences, Inc. Announces Closing of Offering of $517.5 Million of Convertible Senior Notes PR Newswire SAN DIEGO, May 2, 2017 SAN DIEGO, May 2, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has completed its previously announced private offering of $517.5 million... More...>>
04/26/20176:48PMPRNUSNeurocrine Biosciences, Inc. Prices $450.0 Million Convertible Senior Notes Offering
Neurocrine Biosciences, Inc. Prices $450.0 Million Convertible Senior Notes Offering PR Newswire SAN DIEGO, April 26, 2017 SAN DIEGO, April 26, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today the pricing of its offering of $450.0 million aggregate principal amount of 2.25% convertible... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V:us D:20171024 06:04:58